Biotie Shares Drop as Roche Passes on 5-HT6 Drug SYN120
By Cormac Sheridan
Wednesday, June 27, 2012
Shares in Biotie Therapies Oyj dropped nearly 10 percent Tuesday on news that Roche Holding AG decided not to exercise an option on its selective serotonin (5-hydroxytryptamine) receptor subtype 6 (5-HT6) antagonist SYN-120.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.